August 4, 2023 – Medovate announced its SAFIRA® (Safer injection for Regional Anesthesia) has received an Innovative Technology contract from Vizient. The contract has been awarded based on the recommendation of SAFIRA® by hospital experts who serve on one of Vizient’s member-led, hospital and healthcare councils. SAFIRA® was highlighted for its unique qualities, that potentially bring improvement to the healthcare industry.
This prestigious contract is awarded after review and interaction with the product submitted through Vizient’s “Innovative Technology Program” a program that creates visibility to innovative products and services. It is the Vizient members who identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety or improve business operations of healthcare organizations.
The current regional anesthesia procedure typically requires an assistant to inject the anesthetic whilst the anesthetist uses ultrasound guidance to place the needle. SAFIRA® is a novel technology, developed alongside specialist anesthesia clinicians in the UK National Health Service, designed to reduce the risk of nerve injury during regional anesthesia.
The SAFIRA® system automatically limits injection pressure to a specified threshold to help reduce the risk of nerve injury and improve patient safety. In addition, SAFIRA® transforms regional anesthesia into a one-person procedure by enabling anesthetists to conduct the entire nerve block process.
Making regional anesthesia a single-operator procedure further supports the effective application of resources by enabling the anesthetist to take full control of the injection process, removing the need for a second operator, freeing up nursing staff to carry out other critical tasks.